A Phase 2/3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Genetic Diseases, Inborn, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in 5 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.
Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 18th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is the only one in phase 2/3, and was the 56th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
Daniel Bauer · Sites in United States
Ages 13–40
xCures · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 41 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 25 across the 71 interventional studies, 150 across the 17 observational. Of the 50 that completed or were terminated, 17 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 91 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
Vertex Pharmaceuticals Incorporated has 4 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
11 of the studies in beta-Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in beta-Thalassemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
Key Inclusion Criteria:
Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.
Biological: CTX001
Administered by IV infusion following myeloablative conditioning with busulfan
Also known as: Exagamglogene autotemcel, Exa-cel
Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)
Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]
Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days)
Time frame: Within 42 days after CTX001 infusion
Time to neutrophil and platelet engraftment
Time frame: Days post-infusion to engraftment
Frequency and severity of collected adverse events (AEs)
Time frame: Signing of informed consent through Month 24 visit
Incidence of transplant-related mortality (TRM)
Time frame: Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion
All-cause mortality
Time frame: Signing of informed consent through Month 24 visit
Proportion of participants achieving transfusion independence for at least 6 consecutive months (TI6)
Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion
Proportion of participants achieving at least 95 percent (%), 90%, 85%, 75%, and 50% reduction from baseline in annualized volume of RBC transfusions after Month 10 after CTX001 infusion
Time frame: From Month 10 up to 24 months post-CTX001 infusion
Relative reduction from baseline in annualized volume of RBC transfusions after Month 10 after CTX001 infusion
Time frame: From Month 10 up to 24 months post-CTX001 infusion
Duration of transfusion free in participants who have achieved TI12
Time frame: From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion
Proportion of alleles with intended genetic modification in peripheral blood leukocytes over time
Time frame: Day 1 CTX001 infusion through Month 24 visit
Proportion of alleles with intended genetic modification present in CD34+ cells of bone marrow over time
Time frame: Day 1 CTX001 infusion through Month 24 visit
Change in fetal hemoglobin concentration over time
Time frame: Baseline (pre-transfusion) through Month 24 visit
Change in total hemoglobin concentration over time
Time frame: Baseline (pre-transfusion) through Month 24 visit
Change in health-related quality of life (HRQoL) from baseline over time using EuroQol Questionnaire (5 dimensions - 5 levels of severity - EQ-5D-5L)
The EQ-5D-5L Questionnaire consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and 5 levels: no problems to extreme problems. The subject marks the most appropriate statement in each dimension, resulting in a 1-digit number for that dimension. The digits can be combined in a 5-digit number describing the subject's health state. The EQ VAS records the subject's self-rated health on a 100-point VAS, endpoints labelled "the best health you can imagine" and "the worst health you can imagine."
Time frame: Screening visit through Month 24 visit
Change in health-related quality of life (HRQoL) from baseline over time using the Functional assessment of cancer therapy-bone marrow transplant questionnaire (FACT-BMT)
The FACT-BMT Questionnaire includes physical, social, family, emotional, and functional well-being, and treatment specific concerns of bone marrow transplantation. Each statement has a 5-point Likert-type response scale ranging from 0=not at all to 4=very much. The subject marks one number per line as it applies to the past 7 days. Questionnaires are scored; the higher the score, the better the QOL.
Time frame: Screening visit through Month 24 visit
Change in patient reported outcome (PRO) over time assessed using EQ-5D-Youth (EQ-5D-Y)
Time frame: Screening visit through Month 24 visit
Change in PRO over time assessed using pediatric quality of life inventory (PedsQL)
Time frame: Screening visit through Month 24 visit
Changes in liver iron concentration (LIC) and cardiac iron content (CIC) and ferritin parameters of iron overload
Time frame: Screening visit through Month 24 visit
Proportion of participants receiving iron chelation therapy
Time frame: 1 month post-CTX001 infusion through Month 24 visit
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Ran from Sep 2018 to primary completion in Nov 2025, 85 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Exagamglogene autotemcel
Vertex Pharmaceuticals Incorporated →